After nearly 50 years of research, three agents are recommended for use as the platform in colorectal cancer: 5-fluorouracil (5-FU), irinotecan (Camptosar, Pfizer), and oxaliplatin (Eloxatin, Sanofi-Synthelabo). Survival has been correlated with exposure of the patient to all three agents. Despite extending the median survival time for advanced colon cancer to more than 20 months, however, it i...